147 related articles for article (PubMed ID: 12786629)
1. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Sandborn WJ; Sands BE; Wolf DC; Valentine JF; Safdi M; Katz S; Isaacs KL; Wruble LD; Katz J; Present DH; Loftus EV; Graeme-Cook F; Odenheimer DJ; Hanauer SB
Aliment Pharmacol Ther; 2003 Jun; 17(11):1355-64. PubMed ID: 12786629
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
Freytes CO; Ratanatharathorn V; Taylor C; Abboud C; Chesser N; Restrepo A; Arango J; Odenheimer D
Clin Cancer Res; 2004 Dec; 10(24):8318-24. PubMed ID: 15623608
[TBL] [Abstract][Full Text] [Related]
3. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
[TBL] [Abstract][Full Text] [Related]
4. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
J Clin Gastroenterol; 2016 Apr; 50(4):318-25. PubMed ID: 26368296
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers.
Robson MC; Phillips TJ; Falanga V; Odenheimer DJ; Parish LC; Jensen JL; Steed DL
Wound Repair Regen; 2001; 9(5):347-52. PubMed ID: 11896977
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
Tytgat GN; Van Nueten L; Van De Velde I; Joslyn A; Hanauer SB
Aliment Pharmacol Ther; 2002 Jan; 16(1):87-99. PubMed ID: 11856082
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
Naganuma M; Sugimoto S; Mitsuyama K; Kobayashi T; Yoshimura N; Ohi H; Tanaka S; Andoh A; Ohmiya N; Saigusa K; Yamamoto T; Morohoshi Y; Ichikawa H; Matsuoka K; Hisamatsu T; Watanabe K; Mizuno S; Suda W; Hattori M; Fukuda S; Hirayama A; Abe T; Watanabe M; Hibi T; Suzuki Y; Kanai T;
Gastroenterology; 2018 Mar; 154(4):935-947. PubMed ID: 29174928
[TBL] [Abstract][Full Text] [Related]
12. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.
Sandborn WJ; Cyrille M; Hansen MB; Feagan BG; Loftus EV; Rogler G; Vermeire S; Cruz ML; Yang J; Boedigheimer MJ; Abuqayyas L; Evangelista CM; Sullivan BA; Reinisch W
Gastroenterology; 2019 Mar; 156(4):946-957.e18. PubMed ID: 30472236
[TBL] [Abstract][Full Text] [Related]
14. Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study.
Kucharzik T; Lemmnitz G; Abels C; Maaser C
Inflamm Bowel Dis; 2017 Feb; 23(2):261-271. PubMed ID: 28092306
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans.
Sung C; Parry TJ; Riccobene TA; Mahoney A; Roschke V; Murray J; Gu ML; Glenn JK; Caputo F; Farman C; Odenheimer DJ
AAPS PharmSci; 2002; 4(2):E8. PubMed ID: 12102617
[TBL] [Abstract][Full Text] [Related]
18. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
19. Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis.
Jiang XL; Cui HF; Gao J; Fan H
J Clin Gastroenterol; 2015 Aug; 49(7):582-8. PubMed ID: 25844841
[TBL] [Abstract][Full Text] [Related]
20. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
Paramsothy S; Kamm MA; Kaakoush NO; Walsh AJ; van den Bogaerde J; Samuel D; Leong RWL; Connor S; Ng W; Paramsothy R; Xuan W; Lin E; Mitchell HM; Borody TJ
Lancet; 2017 Mar; 389(10075):1218-1228. PubMed ID: 28214091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]